Literature DB >> 31848847

How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review.

Matthew R LeBlanc1, Rachel Hirschey2, Ashley Leak Bryant2, Thomas W LeBlanc3, Sophia K Smith4.   

Abstract

PURPOSE: Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer due in part to changing treatment patterns. It is important to understand how changing treatment patterns affect patients' lives beyond extending survival. Research suggests that direct patient report is the best way to capture information on how patients feel and function in response to their disease and its treatment. Therefore, the purpose of this review is to summarize evidence of patients' experience collected through patient-reported outcomes (PRO) in RRMM patients, and to explore PRO reporting quality.
METHODS: We conducted a systematic search to identify manuscripts reporting PROs in RRMM and summarized available evidence. We assessed PRO reporting quality using the Consolidated Standards of Reporting Trials (CONSORT) PRO Extension checklist.
RESULTS: Our search resulted in 30 manuscripts. Thirteen unique PRO measures were used to assess 18 distinct PRO domains. Pain, fatigue, and emotional function were commonly assessed domains though reporting formats limited our ability to understand prevalence and severity of PRO challenges in RRMM. Evaluation of PRO reporting quality revealed significant reporting deficiencies. Several reporting criteria were included in less than 25% of manuscripts.
CONCLUSIONS: Existing evidence provides a limited window for understanding the patient experience of RRMM and is further limited by suboptimal reporting quality. Observational studies are needed to describe prevalence, severity and patterns of PROs in RRMM overtime. Future studies that incorporate PROs would benefit from following existing guidelines to ensure that study evidence and conclusions can be fully assessed by readers, clinicians and policy makers.

Entities:  

Keywords:  CONSORT PRO; Multiple myeloma; Patient-reported outcomes; Quality of life; Relapsed/refractory multiple myeloma; Systematic review

Mesh:

Year:  2019        PMID: 31848847      PMCID: PMC7428159          DOI: 10.1007/s11136-019-02392-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  64 in total

1.  Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.

Authors:  Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays
Journal:  Cancer       Date:  2014-11-04       Impact factor: 6.860

2.  Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity.

Authors:  Philip S Rosenberg; Kimberly A Barker; William F Anderson
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

3.  Haematological cancer: Where are we now with the treatment of multiple myeloma?

Authors:  Gareth J Morgan; Leo Rasche
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

4.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

Review 5.  Recent advances in the management of multiple myeloma.

Authors:  Lalit Kumar; Rakesh Verma; Venkat Raman Radhakrishnan
Journal:  Natl Med J India       Date:  2010 Jul-Aug       Impact factor: 0.537

6.  The symptom burden of patients with hematological malignancy: a cross-sectional observational study.

Authors:  Vanessa Manitta; Rachel Zordan; Merrole Cole-Sinclair; Harshal Nandurkar; Jennifer Philip
Journal:  J Pain Symptom Manage       Date:  2011-04-07       Impact factor: 3.612

Review 7.  Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis.

Authors:  Christina Ramsenthaler; Pauline Kane; Wei Gao; Richard J Siegert; Polly M Edmonds; Stephen A Schey; Irene J Higginson
Journal:  Eur J Haematol       Date:  2016-09-06       Impact factor: 2.997

8.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

9.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

10.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Paul W Dickman; Asa Rangert Derolf; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544

View more
  7 in total

1.  A cross-sectional observational study of health-related quality of life in adults with multiple myeloma.

Authors:  Matthew R LeBlanc; Ashley Leak Bryant; Thomas W LeBlanc; Qing Yang; Emily Sellars; Cristiana Costa Chase; Sophia K Smith
Journal:  Support Care Cancer       Date:  2022-03-09       Impact factor: 3.359

2.  Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Authors:  Tobias Dechow; Ali Aldaoud; Timo Behlendorf; Wolfgang Knauf; Henning Eschenburg; Matthias Groschek; Richard Hansen; Ulrike Söling; Sina Grebhardt; Hans Ulrich Siebenbach; Corinne Vannier; Karin Potthoff
Journal:  Eur J Haematol       Date:  2021-11-15       Impact factor: 3.674

3.  Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.

Authors:  Alessandra Larocca; Xavier Leleu; Cyrille Touzeau; Joan Bladé; Agne Paner; María-Victoria Mateos; Michele Cavo; Christopher Maisel; Adrían Alegre; Albert Oriol; Anastasios Raptis; Paula Rodriguez-Otero; Amitabha Mazumder; Jacob Laubach; Omar Nadeem; Anna Sandberg; Marie Orre; Anna Torrång; Nicolaas A Bakker; Paul G Richardson
Journal:  Br J Haematol       Date:  2021-10-21       Impact factor: 8.615

4.  Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life.

Authors:  Christopher E Jensen; Sanah N Vohra; Kirsten A Nyrop; Allison M Deal; Matthew R LeBlanc; Shakira J Grant; Hyman B Muss; Eben I Lichtman; Samuel M Rubinstein; William A Wood; Nicholas J Mangieri; Lee Jamison; Sascha A Tuchman
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

5.  Reporting of Patient-Reported Outcome Measures in Randomized Controlled Trials on Shoulder Rotator Cuff Injuries Is Suboptimal and Requires Standardization.

Authors:  Lydia Brock; Brooke Hightower; Ty Moore; Danya Nees; Benjamin Heigle; Samuel Shepard; Micah Kee; Ryan Ottwell; Micah Hartwell; Matt Vassar
Journal:  Arthrosc Sports Med Rehabil       Date:  2022-07-15

Review 6.  Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews.

Authors:  Rebecca Mercieca-Bebber; Olalekan Lee Aiyegbusi; Madeleine T King; Michael Brundage; Claire Snyder; Melanie Calvert
Journal:  Qual Life Res       Date:  2022-03-26       Impact factor: 3.440

Review 7.  Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.

Authors:  Matthew Lyall; Rebecca Crawford; Timothy Bell; Carla Mamolo; Alexander Neuhof; Courtney Levy; Anne Heyes
Journal:  JMIR Cancer       Date:  2022-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.